Desflurane
As of the edition of 20 October 2026, Desflurane is a small molecule: marketed, first approved in 1992 (US); acts on GLRA1, KCNK10 and KCNK18 and 3 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Suprane
- First approved
- 18 September 1992 (US)
- Approvals on record
- 6 in 6 regions
- Holder of the most recent approval
- Baxter Healthcare; 2 holders in all
- Registered trials
- 100, 2 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Mental health; Cancer; Digestive system; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Desflurane.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| KCNK3 | Potassium channel subfamily K member 3 | O14649 |
| KCNK2 | Potassium channel subfamily K member 2 | O95069 |
| GLRA1 | Glycine receptor subunit alpha-1 | P23415 |
| KCNK10 | Potassium channel subfamily K member 10 | P57789 |
| KCNK18 | Potassium channel subfamily K member 18 | Q7Z418 |
| KCNK9 | Potassium channel subfamily K member 9 | Q9NPC2 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 64 | 49 | 5 | 2 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 7 | 6 | 1 | 0 |
| Phase 4 | 26 | 15 | 3 | 0 |
| All trials | 100 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant, Acquired holder and Lead sponsor of trials | 1995 to now |